Results 61 to 70 of about 29,315 (207)

Fondaparinux and acute coronary syndromes: update on the OASIS 5–6 studies

Vascular Health and Risk Management, 2010
François SchieleDepartment of Cardiology, University Hospital Jean-Minjoz, Besançon, FranceAbstract: Anticoagulant therapy is a major component in the management of acute coronary syndromes (ACS).
François Schiele
doaj  

Fitusiran treatment modulates the ratio between alpha‐ and beta‐antithrombin isoforms

HemaSphere, Volume 10, Issue 5, May 2026.
Abstract Antithrombin (AT) circulates as two distinct isoforms, alpha‐ and beta‐AT, which differ in their glycosylation profiles; alpha‐AT is fully glycosylated at positions Asn128, Asn167, Asn187, and Asn224, whereas beta‐AT lacks Asn167 glycosylation.
Geneviève McCluskey, Hortense Maynadié, Delphine Borgel, Laurent Frenzel, Annie Harroche, Elsa Bianchini, Stephanie Roullet, Olivier D. Christophe, Cecile V. Denis, Caterina Casari, Peter J. Lenting   +10 more
wiley   +1 more source

Advances in Chemical Synthesis of Fondaparinux

Journal of Chemistry, 2019
Fondaparinux (trade name Arixtra) is a safe and efficacious anticoagulant, and it is chemically related to low-molecular-weight heparins such as enoxaparin. Fondaparinux is a synthetic pentasaccharide, and its synthesis is difficult and expensive.
Yili Ding, Chamakura V. N. S. Vara Prasad, Bingyun Wang   +2 more
doaj   +1 more source

Fondaparinux Sodium Compared With Low‐Molecular‐Weight Heparins for Perioperative Surgical Thromboprophylaxis: A Systematic Review and Meta‐analysis

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2019
Background Fondaparinux sodium has been compared with low‐molecular‐weight heparins (LMWH) in randomized controlled trials for perioperative surgical thromboprophylaxis.
Arun Kumar, Ashna Talwar, Joel F. Farley, Jagannath Muzumdar, Jon C. Schommer, Rajesh Balkrishnan, Wenchen Wu   +6 more
doaj   +1 more source

Common Practice in the Treatment of Superficial Vein Thrombosis Involving the Sapheno-Femoral Junction: Results from a National Survey of the Italian Society of Angiology and Vascular Medicine (SIAPAV)

Medicina, 2023
Background and Objectives: Prophylactic doses of low-molecular-weight heparins or fondaparinux showed their efficacy and safety for treatment of all superficial vein thrombosis (SVT) of the lower limbs, yet not for those extended to the last 3 cm of the ...
Giuseppe Camporese, Pierpaolo Di Micco, Marcello Di Nisio, Walter Ageno, Romeo Costanzo Martini, Paolo Prandoni   +5 more
doaj   +1 more source

Fucoidan: An Update on Function, Role in Human Health and Applications

Chemical Biology &Drug Design, Volume 107, Issue 5, May 2026.
Fucoidan is a promising bioactive compound with anti‐inflammatory, anticoagulant, anticancer, antioxidant, antiviral, and cardioprotective properties. In addition, thanks to its epigenetic potential, ability to modulate autophagic mechanisms and possibility adjuvant agent or bioactive component of the drug delivery systems, fucoidan is a promising ...
Sharon Critelli, Marilena Celano
wiley   +1 more source

Fully Synthetic Non‐Carbohydrate Heparin Mimetics—Perspectives for Therapeutic Anticoagulation and Beyond?

Archiv der Pharmazie, Volume 359, Issue 4, April 2026.
Fully synthetic sulfated non‐carbohydrate polymers for structurally mimicking the polysaccharide glycosaminoglycan heparin in its anticoagulant activities with further prospects to pleiotropic effects in oncology and in antiviral approaches. ABSTRACT Heparin is one of the oldest drugs on the market.
Katrin Nekipelov, Vito Ferro, Gerd Bendas   +2 more
wiley   +1 more source

Spontaneous Coronary Artery Dissection : The Phantom Menace [PDF]

, 2016
Articles © The authorsWe present a case of a 66-year-old lady with chest pain, without dynamic 12-lead electrocardiographic (ECG) changes and normal serial troponin. Coronary angiography revealed a linear filing defect in the first obtuse marginal branch
Abdulkareem, Nada, Farag, Mohamed, Gorog, Diana A, Spinthakis, Nikolaos   +3 more
core   +3 more sources

Classification of Platelet‐Activating Anti‐Platelet Factor 4 Disorders

International Journal of Laboratory Hematology, Volume 48, Issue 2, Page 259-271, April 2026.
ABSTRACT Introduction The prototypic anti‐platelet factor 4 (PF4) disorder—heparin‐induced thrombocytopenia and thrombosis (HITT)—features immunoglobulin G (IgG) class antibodies that activate platelets, monocytes, and neutrophils in a mainly heparin‐dependent fashion via Fcγ receptor‐dependent cellular activation.
Theodore E. Warkentin
wiley   +1 more source

Clinical Profile and Admission Outcomes of Patients With Acute Pulmonary Embolism at a Resource‐Constrained Hospital in Ghana: A Retrospective Pilot Study

Health Science Reports, Volume 9, Issue 3, March 2026.
ABSTRACT Background and Aims Pulmonary embolism is a cardiovascular disease associated with significant morbidity and mortality. There is a paucity of literature regarding this condition from the Ghanaian perspective. This study aimed at evaluating the clinical profile and admission outcomes of patients with acute pulmonary embolism at the Methodist ...
Prosper Adjei, Samuel Kyeremeh Adjei, Kingsley Owusu Manu   +2 more
wiley   +1 more source